>>Signaling Pathways>> Proteases>> Caspase>>KEA1-97

KEA1-97

Catalog No.GC63031

KEA1-97은 선택적 티오레독신-카스파제 3 상호작용 교란물질(IC50=10μM)입니다. KEA1-97은 thioredoxin과 caspase 3의 상호작용을 방해하고 caspase를 활성화하며 thioredoxin 활성에 영향을 미치지 않으면서 세포자멸사를 유도합니다.

Products are for research use only. Not for human use. We do not sell to patients.

KEA1-97 Chemical Structure

Cas No.: 2138882-71-8

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$69.00
재고 있음
5 mg
US$63.00
재고 있음
10 mg
US$99.00
재고 있음
25 mg
US$197.00
재고 있음
50 mg
US$342.00
재고 있음
100 mg
US$549.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

KEA1-97 is a selective Thioredoxin-caspase 3 interaction disruptor (IC50=10 μM). KEA1-97 disrupts the interaction of thioredoxin with caspase 3, activates caspases, and induces apoptosis without affecting thioredoxin activity[1].

KEA1-97 (100 μM; 231MFP cells) impaires thioredoxin pulldown of caspase 3[1].KEA1-97 (10 μM; 48 hours; 231MFP cells) impaires 231MFP serum-free cell proliferation[1].KEA1-97 (10 μM; 0~12 hours; 231MFP cells) activates caspase 3/7 and induces apoptotic cell death[1].KEA1-97 (231MFP cells) resistants to survival and proliferation impairments[1].

KEA1-97 (5 mg/kg; i.p.; 50 days) attenuates tumor xenograft growth[1].

[1]. Anderson KE, et al. Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity. ACS Chem Biol. 2017;12(10):2522-2528.

리뷰

Review for KEA1-97

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for KEA1-97

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.